

FORM 3

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549**

OMB APPROVAL	
OMB Number:	3235-0104
Expires:	November 30, 2011
Estimated average burden hours per response...	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * LEDERMAN SETH (Last) (First) (Middle) C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306 (Street) NEW YORK, NY 10022 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 01/14/2013	3. Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Chief Executive Officer	5. If Amendment, Date Original Filed(Month/Day/Year)
		6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, Par Value \$0.001	746,165	D	
Common Stock, Par Value \$0.001	3,692,558	I	Lederman & Co., LLC (1)
Common Stock, Par Value \$0.001	649,138	I	L&L Technologies, LLC (1)
Common Stock, Par Value \$0.001	1,179,424	I	Targent Pharmaceuticals, LLC (1)
Common Stock, Par Value \$0.001	83,333	I	Leder Laboratories, Inc. (1)
Common Stock, Par Value \$0.001	83,333	I	Starling Pharmaceuticals, Inc. (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Warrants	01/20/2012	01/20/2017	Common Stock	90,000	\$ 1.25	I	Lederman & Co., LLC (1)
Warrants	12/04/2012	12/04/2017	Common Stock	1,000,000	\$ 0.6	I	Lederman & Co., LLC (1)
			Common				Lederman & Co

Warrants	12/04/2012	12/04/2013	Common Stock	1,000,000	\$ 0.4	I	Lederman & Co., LLC (1)
Warrants	01/20/2012	01/20/2015	Common Stock	10,000	\$ 1	I	L&L Technologies, LLC (1)
Warrants	01/20/2012	01/20/2017	Common Stock	10,000	\$ 1.25	I	L&L Technologies, LLC (1)
Warrants	12/04/2012	12/04/2017	Common Stock	233,333	\$ 0.6	I	L&L Technologies, LLC (1)
Warrants	12/04/2012	12/04/2013	Common Stock	233,333	\$ 0.4	I	L&L Technologies, LLC (1)
Warrants	01/20/2012	01/20/2017	Common Stock	165,000	\$ 1.25	I	Targent Pharmaceuticals, LLC (1)
Warrants	12/04/2012	12/04/2017	Common Stock	83,333	\$ 0.6	I	Leder Laboratories, Inc. (1)
Warrants	12/04/2012	12/04/2013	Common Stock	83,333	\$ 0.4	I	Leder Laboratories, Inc. (1)
Warrants	12/04/2012	12/04/2017	Common Stock	83,333	\$ 0.6	I	Starling Pharmaceuticals, Inc. (1)
Warrants	12/04/2012	12/04/2013	Common Stock	83,333	\$ 0.4	I	Starling Pharmaceuticals, Inc. (1)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
LEDERMAN SETH C/O TONIX PHARMACEUTICALS HOLDING CORP 509 MADISON AVE., SUITE 306 NEW YORK, NY 10022	X	X	Chief Executive Officer	

Signatures

/s/ Seth Lederman		01/14/2013
**Signature of Reporting Person		Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Reporting person may be deemed to be a control person of this entity.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.